Colorectal cancer and the relationship between genes and the environment

Nutrition and Cancer

Volumn 48, Issue 2, 2004, Pages 124-141

  Heavey, Patricia M ^a   McKenna, Declan ^a   Rowland, Ian R ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; APC PROTEIN; CALCIUM; CD30 ANTIGEN; CELECOXIB; FOLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN MLH1; PROTEIN MSH2; PROTEIN P53; RAS PROTEIN; SEX HORMONE; TRACE ELEMENT;

ALCOHOL CONSUMPTION; ANTINEOPLASTIC ACTIVITY; CALCIUM INTAKE; CANCER RISK; CARCINOGENESIS; CHROMOSOME 18Q; CLINICAL TRIAL; COLORECTAL CANCER; DIETARY FIBER; DIETARY INTAKE; ENVIRONMENTAL FACTOR; FAMILY HISTORY; GENE; HEREDITY; HORMONE SUBSTITUTION; HUMAN; INHERITANCE; LOW FAT DIET; MEAT; MISMATCH REPAIR; MISMATCH REPAIR GENE; ONCOGENE; PENETRANCE; PHYSICAL ACTIVITY; PROTECTION; REVIEW; RISK FACTOR; SMOKING; TUMOR SUPPRESSOR GENE; VEGETABLE;

EID: 3843138426     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1207/s15327914nc4802_2     Document Type: Review

References (205)

1. Bingham SA: Epidemiology and mechanisms relating to risk of colorectal cancer. Nutr Res Rev 9, 197-239, 1996.
2. Nagata C, Shimizu H, Kametani M, Takeyama N, Ohnuma T, et al.: Diet and colorectal cancer in Japanese males and females. Dis Colon Rectum 44, 105-111, 2001.
3. Haenszel W: Cancer mortality among the foreign born in the U.S. JNCI 26, 37-132, 1961.
4. Buell P and Dunn JE: Cancer mortality among Japanese issii and nisei of California. Cancer 18, 656-664, 1965.
5. Staszewski J and Haenszel W: Cancer mortality among the Polish born in the U.S. JNCI 35, 291-297, 1965.
6. Haenszel W and Kurihara M: Mortality from cancer and other diseases among Japanese in the United States. JNCI 40, 43-68, 1968.
7. Pisa FE, Barbone F, Montella M, Talamini R, La Vecchia C, et al.: Migration, socio-economic status and the risk of colorectal cancer in Italy. Eur J Cancer Prev 9, 409-416, 2000.
8. Potter JD. Colorectal cancer: Molecules and populations. JNCI 91, 916-932, 1999.
9. Augenlicht LH, Heerdt BG, Mariadason JM, Yang W, Wilson AJ, et al.: Environment-gene interactions in intestinal cancer. Eur J Cancer Prev 11, S12-S17, 2002.
10. Bruce WR, Giacca A, and Medline A: Possible mechanisms relating diet to colorectal cancer risk. IARC Scientific Publications 156, 277-281, 2002.
11. Norat T and Riboli E: Dairy products and colorectal cancer. A review of possible mechanisms and epidemiological evidence. Eur J Clin Nutr 57, 1-17, 2003.
12. Shih M, Wang TL, Traverso G, Romans K, Hamilton SR, et al.: Top-down morphogenesis of colorectal tumors. Proc Natl Acad Sci USA 98, 2640-2645, 2001.
13. Fearon ER and Vogelstein B: A genetic model for colorectal tumorgenesis. Cell 61, 759-767, 1990.
14. Powell SM, Zilz N, Beazer-Barclay Y, Bryan TM, Hamilton SR, et al.: APC mutations occur early during colorectal tumorigenesis. Nature 359, 235-237, 1992.
15. 1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development. Genes Dev 13, 1309-1321, 1999.
16. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, et al.: Identification of c-MYC as a target of the APC pathway. Science 281, 1509-1512, 1998.
17. Tetsu O and McCormick F: β-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398, 422-426, 1999.
18. Dimberg J, Hugander A, Sirsjo A, and Soderkvist P: Enhanced expression of cyclooxygenase-2 and nuclear beta-catenin are related to mutations in the APC gene in human colorectal cancer. Anticancer Res 21, 911-915, 2001.
19. Rowan AJ, Lamlum H, Ilyas M, Wheeler J, Straub J, et al.: APC mutations in sporadic colorectal tumors: a mutational "hotspot" and interdependence of the "two hits." Proc Natl Acad Sci USA 97, 3352-3357, 2000.
20. Bos JL, Fearon ER, Hamilton ER, Verlaande Vries M, and Vander AJ: Prevalence of ras mutations in human colorectal cancers. Nature 327, 293-297, 1987.
21. Vogelstein BER, Fearon SR, Hamilton SE, Kern AC, Preisinger M, et al.: Genetic alterations during colorectal tumor development. N Engl J Med 319, 525-532, 1988.
22. Cho KR, Vogelstein B: Suppressor gene alterations in the colorectal adenoma-carcinoma sequence. J Cell Biochem 16G, 137-141,1992.
23. Baker SJ, Fearon ER, Nigro JM, Hamilton SR, Preisinger AC, et al.: Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 244, 217-221, 1989.
24. Lane DP: Cancer. p53, guardian of the genome. Nature 358, 15-16, 1992.
25. Greenblatt MS, Bennett WP, Hollstein M, and Harris CC: Mutations in the p53 tumor-suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54, 4855-4878, 1994.
26. Keino-Masu K, Masu M, Hinck L, Leonardo ED, Chan SS, et al.: Deleted in colorectal cancer (DCC) encodes a netrin receptor. Cell 87, 175-185, 1996.
27. Thiagalingam S, Lengauer C, Leach FS, Schutte M, Hahn SA, et al.: Evaluation of candidate tumor suppressor genes on chromosome 18 in colorectal cancers. Nat Genet 13, 343-346, 1996.
28. Xu W, Angelis K, Danielpour D, Haddad MM, Bischof O, et al.: Ski acts as a co-repressor with Smad 2 and Smad 3 to regulate the response to type beta transforming growth factor. Proc Natl Acad Sci USA 97, 5924-5929, 2000.
29. Massagúe J: How cells read TGF-β signals. Nat Rev Mol Cell Biol 1, 169-178, 2000.
30. Massague J and Polyak K: Mammalian antiproliferative signals and their targets. Curr Opin Genet Dev 5, 91-96, 1995.
31. Veale AMO: Intestinal Polyposis. Eugenics Laboratory Memoirs. Series no. 40. London: Cambridge University Press, 1965.
32. Lamlum H, Ilyas M, Rowan A, Clark S, Johnson V, et al.: The type of somatic mutation at APC in familial adenomatous polyposis is determined by the site of the germline mutation: a new facet to Knudson's "two-hit" hypothesis. Nat Med 5, 1071-1075, 1999.
33. Lynch HT and Lynch JF: Hereditary non-polyposis colorectal cancer (Lynch Syndrome I & II): a common genotype linked to oncogenes? Med Hypotheses 18, 19-28, 1985.
34. Lynch HT and de la Chapelle A: Genetic susceptibility to non-polyposis colorectal cancer. J Med Genet 36, 801-818, 1999.
35. Salahshor S, Kresssner U, Pahlman L, Glimelius B, Lindmark G, et al.: Colorectal cancer with and without microsatellite instability involves different genes. Genes Chromosom Cancer 26, 247-252, 1999.
36. Grady WM: Genetic testing for high-risk colon cancer patients. Gastroenterology 124, 1574-1594, 2003.
37. Peltomaki P, Aaltonen LA, Sistonen P, Pylkkanen L, Mecklin JP, et al.: Genetic mapping of a locus predisposing to human colorectal cancer. Science 260, 810-812, 1993.
38. Lawes DA, SenGupta S, Boulos PB: The clinical importance and prognostic implications of microsatellite instability in sporadic cancer. Eur J Surg Oncol 29, 201-212, 2003.
39. Parsons R, Myeroff LL, Liu B, Willson JKV, Markowitz SD, et al.: Microsatellite instability and mutations of the transforming growth factor β-type II receptor gene in colorectal cancer. Cancer Res 57, 300-303, 1995.
40. Grady WH, Rajput A, Myeroff L, Liu DF, Kwon K, et al.: Mutation of the Type II transforming growth factor-beta receptor is coincident with the transformation of human colon adenomas to malignant carcinomas. Cancer Res 58, 3101-3104, 1998.
41. Hamilton SR: The adenoma-adenomacarcinoma sequence in the large bowel: variation on a theme. J Cell Biochem 16G, 41-46, 1992.
42. Hiltunen MO, Koistinaho J, Alhonen L, Myohanen S, Marin S, et al.: Hypermethylation of the WT1 and calcitonen gene promoter regions at chromosome 11p in human colorectal cancer. Br J Cancer 76, 1124-1130, 1997.
43. Razin A and Riggs AD: DNA methylation and gene function. Science 210, 604-610, 1980.
44. Feinberg A and Vogelstein B: Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301, 89-92, 1983.
45. Makos M, Nelkin B, Lerman M, Latif F, Zbar B, et al.: Distinct hypermethylation patterns occur altered chromosome loci in human lung and colon cancer. Proc Natl Acad Sci USA 89, 1929-1933, 1992.
46. Feinberg AP, Gehrke CW, Kuo KC, and Ehrlich M: Reduced genomic 5-methylcytosine content in human colonic neoplasia. Cancer Res 48, 1159-1161, 1988.
47. Issa JP: Aging, DNA methylation and cancer. Crit Rev Oncol Hematol 32, 5438-5442, 1999.
48. Esteller M, Sparks A, Toyota M, Sanchez-Cespedes M, Capella G, et al.: Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res 60, 4366-4371, 2000.
49. Nakagawa H, Nuovo GJ, Zervos EE, Martin EW, Salovaara R, et al.: Age-related hypermethylation of the 5′ region of MLH1 in normal colonic mucosa is associated with microsatellite-unstable colorectal cancer development. Cancer Res 61, 6991-6995, 2001.
50. Suter CM, Norrie M, Ku SL, Cheong KF, Tomilson I, et al.: CpG island methylation is a common finding in colorectal cancer cell lines. Br J Cancer 88, 413-419, 2003.
51. Slattery ML, Potter JD, Samowitz W, Schaffer D, and Leppert M: Methylenetetrahydrofolate Reductase, diet and risk of colon cancer. Cancer Epidemiol Biomarkers Prev 8, 513-518, 1999.
52. Autrup H: Genetic polymorphisms in human xenobiotica metabolizing enzymes as susceptibility factors in toxic response. Mutat Res 464, 65-76, 2000.
53. Murata M, Tagawa M, Watanabe S, Kimura H, Takshita T, et al.: Genotype difference of aldehyde dehydrogenase 2 gene in alcohol drinkers influences the incidence of Japanese colorectal cancer patients. Jpn J Cancer Res 90, 711-719, 1999.
54. Ulrich CM, Kampman E, Bigler J, Scwartz SM, Chen C, et al.: Colorectal adenomas and the C677T MTHFR polymorphism: evidence for gene-environment interaction? Cancer Epidemiol Biomarkers Prev 8, 659-668, 1999.
55. Lin HJ, Probst-Hensch NM, Louie AD, Kau IH, Witte JS, et al,: Glutathione transferase null genotype, broccoli and lower prevalence of colorectal adenomas. Cancer Epidemiol Biomarkers Prev 7, 647-652, 1998.
56. Slattery ML, Potter JD, Ma K-N, Caan BJ, Leppert M, et al.: Western diet, family history of colorectal cancer, NAT2, GSTM1 and risk of colon cancer. Cancer Causes Control 11, 1-8, 2000.
57. Roberts-Thomson IC, Ryan P, Khoo KK, Hart WJ, McMichael AJ, et al.: Diet, acetylator phenotype, and risk of colorectal neoplasia. Lancet 347, 1372-1374, 1996.
58. Chen J, Stampfer MJ, Hough HL, Garcia-Closas M, Willet WC, et al.: A prospective study of N-acetyltransferase genotype, red meat intake and risk of colorectal cancer. Cancer Res 58, 3307-3311, 1998.
59. Kampman E, Slattery ML, Bigler J, Leppert M, Samowitz W, et al.: Meat consumption, genetic susceptibility and colon cancer risk: a United States multicenter case-control study. Cancer Epidemiol Biomarkers Prev 8, 15-24, 1999.
60. Wagner C: Biochemical role of folate in cellular metabolism. In Folate in Health and Disease, Bailey LB (ed). New York: Marcel Dekker, 1995, pp 313-328.
61. Baylin SB, Makos M, We J, Chiu Yen RW, and de Bustros A: Abnormal patterns of DNA methylation in human neoplasia: potential consequences for tumor progression. Cancer Cells 3, 382-390, 1991.
62. Frosst P, Blom BS, Milos R, Goyette P, and Sheppard CA: A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10, 111-113, 1995.
63. Brockton N, Little J, Sharp L, and Cotton SC: N-acetyltransferase polymorphisms and colorectal cancer: a HuGE review. Am J Epidemiol 151, 846-861, 2000.
64. Hein DW: N-acetyltransferase genetics and their role in predisposition to aromatic and heterocyclic amine-induced carcinogenesis. Toxicol Lett 112-113, 349-356, 2000.
65. Garcea G, Sharma RA, Dennison A, Stewart WP, Gescher A, et al.: Molecular biomarkers of colorectal carcinogenesis and their role in surveillance and early intervention. Eur J Cancer 39, 1041-1052, 2003.
66. Cotton SC, Sharp L, Little J, and Brockton N: Glutathione S-transferase polymorphisms and colorectal cancer: a huGE review. Am J Epidemiol 151, 7-32, 2000.
67. Welfare M, Monesola Adeeokun A, Bassendine MF, and Daly AK: Polymorphisms in GSTP1, GSTM1 and GSTT1 and susceptibility to colorectal cancer. Cancer Epidemiol Biomarkers Prev 8, 289-292, 1992.
68. Loktionov A, Watson MA, Gunter M, Stebbings WS, Speakman CT, et al.: Glutathione-S-transferase gene polymorphisms in colorectal cancer patients: interaction between GSTM1 and GSTM3 allele variants as a risk -modulating factor. Carcinogenesis 22, 1053-1060, 2001.
69. Willett WC: Diet, nutrition and avoidable cancer. Environ Health Perspect 103, 165-170, 1995.
70. World Cancer Research Fund/American Institute for Cancer Research. Food, Nutrition and the Prevention of Cancer: A Global Perspective. Washington, DC: WCRF/AICR, 1997.
71. COMA Working Group on Diet and Cancer. Nutritional aspects of the development of cancer: UK Department of Health Report on Health and Social Subjects (No. 48). Norwich: HMSO, 1998.
72. Willett WC: Diet and cancer. Oncologist 5, 393-404, 2000.
73. Breuer-Katschinski B, Nemes K, Marr A, Rump B, Leiendecker B, et al.: Colorectal adenomas and diet: a case-control study. Colorectal Adenoma Study Group. Dig Dis Sci 46, 86-95, 2001.
74. Norat T and Riboli E: Meat consumption and colorectal cancer: a review of epidemiological evidence. Nutr Rev 59, 37-47, 2001.
75. Sandhu MS, White IR, and McPherson K: Systematic review of the prospective cohort studies on meat consumption and colorectal cancer risk: a meta-analytical approach. Cancer Epidemiol Biomarkers Prev 10, 439-446, 2001.
76. Linseisen J, Kesse E, Slimani N, Bueno-De-Mesquita HB, Ocke MC, et al.: Meat consumption in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohorts: results from 24-hour dietary recalls. Pub Health Nutr 5, 1243-1258, 2002.
77. Elmstahl S, Holmqvist O, Gullberg B, Johansson U, and Berglund G: Dietary patterns in high and low consumers of meat in a Swedish cohort study. Appetite 32, 191-206, 1999.
78. Hughes R, Cross AJ, Pollock JRA, Bingham S: Dose-dependent effect of dietary meat on endogenous colonic N-nitrosation. Carcinogenesis 22, 199-202, 2001.
79. Wurzemann JI, Silver A, Schreinemachers DM, Sandler RS, and Everson RB: Iron intake and risk of colon cancer. Cancer Epidemiol Biomarkers Prev 5, 503-507, 1996.
80. Lund EK, Wharf SG, Fairweather-Tait SJ, and Johnson IT: Oral ferrous sulphate supplements increase the free radical-generating capacity of feces from healthy volunteers. Am J Clin Nutr 69, 250-255, 1999.
81. Sinha R, Kulldorff M, Chow WH, Denobile J, and Rothman N: Dietary intake of heterocyclic amines, meat-derived mutagenic activity, and risk of colorectal adenomas. Cancer Epidemiol Biomarkers Prev 10, 559-562, 2001.
82. Lang NP, Butler MA, Massengill J, Lawson M, Stotts RC, et al.: Rapid metabolic phenotypes for acetyltransferase and cytochrome P4501A2 and putative exposure to food-borne heterocyclic amines increase the risk for colorectal cancer or polyps, Cancer Epidemiol Biomarkers Prev 3, 675-682, 1994.
83. Ladero JM, Gonzalez JF, Benitez J, Vargas E, Fernandez MJ, et al.: Acetylator polymorphism in human colorectal carcinoma. Cancer Res 51, 2098-2100, 1991.
84. Shibuta K, Nakashima T, Abe M, Mashimo M, Mori M, et al.: Molecular genotyping for N-acetylation polymorphism in Japanese patients with colorectal cancer. Cancer 74, 3108-3112, 1994.
85. Marchand LL: Combined influence of genetic and dietary factors on colorectal cancer incidence in Japanese Americans. JNCI 26, 101-105, 1999.
86. Sharpe CR, Siemiatycki J, and Rachet B: Effects of alcohol consumption on the risk of colorectal cancer among men by anatomical subsite (Canada). Cancer Causes Control 13, 493-491, 2002.
87. Bardou M, Montembault S, Giraud V, Balian A, Borotto E, et al.: Excessive alcohol consumption favours high risk polyp or colorectal cancer occurrence among patients with adenomas: a case control study. Gut 50, 38-42, 2002.
88. Shimizu N, Nagata C, Shimizu H, Kametani M, Takeyama N, et al.: Height, weight and alcohol consumption in relation to the risk of colorectal cancer in Japan: a prospective study. Br J Cancer 88, 1038-1043, 2003.
89. Breuer-Katschinski B, Nemes K, Marr A, Rump B, Leiendecker B, et al.: Alcohol and cigarette smoking and the risk of colorectal adenomas. Dig Dis Sci 45, 487-493, 2000.
90. Ye W, Romelsjo A, Augustsson K, Adami HO, and Nyren O: No excess risk of colorectal cancer among alcoholics followed for up to 25 years. Br J Cancer 88, 1044-1046, 2003.
91. Jacobson JS, Neagut AI, Murray T, Garbowski GC, Forde KA, et al.: Cigarette smoking and other behavioral risk factors for recurrence of colorectal adenomatous polyps (New York City, NY, USA). Cancer Causes Control 5, 215-220, 1994.
92. Slattery ML, Anderson K, Curtin K, Khe-Ni M, Schaffer D, et al.: Dietary intake and microsatellite instability in colon tumors. Int J Cancer 93, 601-607, 2001.
93. Kune GA, Vetetta L: Alcohol consumption and the etiology of colorectal cancer: a review of the scientific evidence from 1957 to 1991. Nutr Cancer 18, 97-111, 1992.
94. Franceschi S: Nutrient and food groups and large bowel cancer in Europe. Eur J Cancer Prev 8, S49-S52, 1999.
95. Slattery ML, Potter JD, Coates A, Ma KN, Berry TD, et al.: Plant foods and colon cancer: an assessment of specific foods and their related nutrients. Cancer Causes Control 8, 575-590, 1997.
96. Bueno-De-Mesquita HB: Plant foods and colorectal cancer in the EPIC cohort. Proceedings of the European Conference on Nutrition and Cancer. 11 abstr, 2001.
97. Voorrips LE, Goldbohm RA, van Poppel G, Sturmans F, Hermus RJ, et al.: Vegetable and fruit consumption and risks of colon and rectal cancer in a prospective cohort study: The Netherlands Cohort Study on Diet and Cancer. Am J Epidemiol 152, 1081-1092, 2000.
98. Michels KB, Giovannucci E, Joshipura KJ, Rosner BA, Stampfer MJ, et al.: Fruit and vegetable consumption and colorectal cancer incidence. IARC Sci Publications 156, 139-140, 2002.
99. Steinmetz KA and Potter JD: Food-group consumption and colon cancer in the Adelaide case-control study. I. Vegetables and fruit. Int J Cancer 53, 711-719, 1993.
100. Levi F, Pasche C, Lucchini F, and La Vecchia C: Selected micronutrients and colorectal cancer; a case-control study from the canton of Vaud, Switzerland. Eur J Cancer 36, 2115-2119, 2000.
101. Verhoeven DT, Goldbohm RA, van Poppel G, Verhagen H, and van den Brandt PA: Epidemiological studies on brassica vegetables and cancer risk. Cancer Epidemiol Biomarkers Prev 5, 733-748, 1996.
102. Jacobs EJ, Connell CJ, Patel AV, Chao A, Rodriguez C, et al.: Vitamin C and vitamin E supplement use and colorectal cancer mortality in a large American Cancer Society cohort. Cancer Epidemiol Biomarkers Prev 10, 17-23, 2001.
103. Whelan RL, Horrath KD, Gleason NR, Forde KA, Treat MD, et al.: Vitamin and calcium supplement use is associated with decreased adenoma recurrence in patients with a previous history of neoplasia. Dis Colon Rectum 42, 212-217, 1999.
104. Ramos-Gomez M, Kwak MK, Dolan PM, Itoh K, Yamamoto M, et al.: Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc Natl Acad Sci USA 98, 3410-3415, 2001.
105. Nastruzzi C, Cortesi R, Esposito E, Menegatti E, Leoni O, et al.: In vitro antiproliferative activity of isothiocyanates and nitriles generated by myrosinase-mediated hydrolysis of glucosinolates from seeds of cruciferous vegetables. J Agric Food Chem 48, 3572-3575, 2000.
106. Lin HJ, Probst-Hensch NM, Louie AD, Kau IH, Witte JS, et al.: Glutathione transferase null genotype, broccoli and lower prevalence of colorectal adenomas. Cancer Epidemiol Biomarkers Prev 7, 647-652, 1998.
107. Cotton SC, Sharp L, Little J, and Brockton N: Glutathione S-transferase polymorphisms and colorectal cancer: a huGE review. Am J Epidemiol 151, 7-32, 2000.
108. Probst-Hensch NM, Haile RW, Ingles SA, Longnecker MP, Han CV, et al.: Lack of association between the polyadenylation polymorphism in the NAT1 (acetyltransferase 1) gene and colorectal adenomas. Carcinogenesis 17, 2125-2129, 1996.
109. Roberts-Thomson IC, Ryan P, Khoo KK, Hart WJ, McMichael AJ, et al.: Diet, acetylator phenotype, and risk of colorectal neoplasia. Lancet 347, 1372-1374, 1996.
110. Slattery ML, Curtin K, Anderson K, Ma K, Edwards S, et al.: Associations between dietary intake and ki-ras mutations in colon tumors: a population-based study. Cancer Res 60, 6935-6941, 2000.
111. Higginson J and Oettle AG: Cancer incidence in Bantu and "Cape colored" races of South Africa: report of a cancer survey of the Transvaal (1953-1955). JNCI 24, 589-671, 1960.
112. Burkitt DP: Related disease, related cause? Lancet 2, 1229-1231, 1969.
113. Trock B, Lanza E, and Greenwald P: Dietary fiber, vegetables, and colon cancer: critical review and meta-analysis of the epidemiologic evidence. JNCI 82, 650-661, 1990.
114. Peters U, Sinha R, Chattergie N, Subar AF, Ziegler RG, et al.: Dietary fiber and colorectal adenoma in a colorectal cancer early detection programme. Lancet 361, 491-495, 2003.
115. Bingham SA, Day NE, Luben R, Ferrari P, Norat T, et al.: Dietary fiber in food and protection against colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC); an observational study. Lancet 361, 1496-1501, 2003.
116. Fuchs CS, Giovannuci EL, Colditz GA, Hunter DJ, Stampfer MJ, et al.: Dietary fiber and the risk of colorectal cancer and adenoma in women. N Engl J Med 340, 169-176, 1999.
117. Ferguson LR and Harris PJ: The dietary fiber debate: more food for thought. Lancet 361, 1487-1488, 2003.
118. Cummings JH: Dietary fiber and large bowel cancer. Proc Nutr Soc 40, 7-14, 1981.
119. Silvi S, Rumney CJ, Cresci A, and Rowland IR: Resistant starch modifies gut microflora and microbial metabolism in human flora-associated rats inoculated with faces from Italian and UK donors. J Appl Microbiol 86, 521-530, 1999.
120. Edwards CA, Rowland IR: Bacterial fermentation in the colon and its measurement. In Dietary Fiber, A Component of Food, Nutritional Function in Health and Disease, Schweizer T and Edwards CA (eds). Europe: ILSI, 1991, pp 119-136.
121. Rowland IR: Non-digestible carbohydrates and gut function: implications for carcinogenesis. In Advanced Dietary Fiber Technology, McCleary BV and Prosky L (eds). Oxford: Blackwell Science, 2000, pp 226-231.
122. Roediger WE: The starved colon-diminished mucosal nutrition, diminished absorption, and colitis Dis Colon Rectum 33, 858-862, 1990.
123. Scheppach W: Effects of short chain fatty acids on gut morphology and function. Gut Suppl. 1, S35-S38, 1994.
124. Heerdt BG, Houston MA, and Augenlicht LH: Short-chain fatty acid-initiated cell cycle arrest and apoptosis of colonic epithelial cells is linked to mitochondrial function. Cell Growth Differ 8, 523-532, 1997.
125. Chai F, Evdokiou A, Young GP, and Zalewski PD: Involvement of p21 (Waf1/Cip1) and its cleavage by DEVD-caspase during apoptosis of colorectal cancer cells induced by butyrate. Carcinogenesis, 21, 7-14, 2000.
126. Chapkin RS, Fan Y, and Lupton JR: Effect of diet on colonic programmed cell death: molecular mechanism of action. Toxicol Lett 112-113, 411-414, 2000.
127. Rosignoli P, Fabiani R, De Bartolomeo A, Spinozzi F, Agea E, et al.: Protective activity of butyrate on hydrogen peroxide -induced DNA damage in isolated human colonocytes and HT29 tumor cells. Carcinogenesis 22, 1675-1680, 2001.
128. Richon VM, Sandhoff TW, Rifkind RA, and Marks PA: Histone deacetylase inhibitors selectively induces p21 super (WAF1) expression and gene associated histone acetylation. Proc Natl Acad Sci USA 97, 10014-10019, 2000.
129. Boffa LC, Lupton JR, Mariani MR, Ceppi M, Newmark HL, et al.: Modulation of colonic epithelial cell proliferation, histone acetylation, and luminal short chain fatty acids by variation of dietary fiber (wheat bran) in rats. Cancer Res 52, 5906-5912, 1992.
130. Nigro ND, Bull AW, Klopfer BA, Paks MS, and Campbell RL: Effects of dietary fiber on azoxymethane-induced intestinal carcinogenesis in rats. JNCI 62, 1097-1102, 1979.
131. Hardman WE and Cameron IL: Site-specific reduction of colon cancer incidence, without a concomitant reduction in cryptal cell proliferation, in 1, 2-dimethylhydrazine-treated rats by diets containing 10% pectin with 5% or 20% corn oil. Carcinogenesis 16, 1425-1431, 1995.
132. Ishizuka S, Sonoyama K, and Kassai T: Changes in the number and apoptosis of epithelial cells in the colorectum of wheat bran-fed rats soon after administering 1,2-dimethylhydrazine. Biosci Biotechnol Biochem 61, 1337-1341, 1997.
133. Caderni G, Luceri C, De Filippo C, Salvadori M, Giannini A, et al.: Slow-release pellets of sodium butyrate do not modify azoxymethane (AOM)-induced intestinal carcinogenesis in F344 rats. Carcinogenesis 22, 525-527, 2001.
134. Bird AR, Brown IL, and Topping DL: Starches, resistant starches, the gut microflora and human health. Curr Issues in Intest Microbiol 1, 25-37, 2000.
135. McIntyre A, Gibson PR, and Young GP: Butyrate production from dietary fiber and protection against large bowel cancer in a rat model. Gut 34, 386-391, 1993.
136. Mobarhan S: Calcium and the colon: recent findings. Nutr Rev 57, 124-129, 1999.
137. Pietinen P, Malila N, Virtanen M, Hartman JJ, Tangree JA, et al.: Diet and risk of colorectal cancer in a cohort of Finnish men. Cancer Causes Control 10, 389-396, 1999.
138. Marcus PM and Newcomb PA: The association of calcium and vitamin D, and colon and rectal cancer in Wisconsin women. Int J Epidemiol 37, 788-793, 1998.
139. Penman ID, Liang QL, Bode J, Eastwood MA, and Arench MJ: Dietary calcium supplementation increases apoptosis in the distal murine colonic epithelium. J Clin Pathol 53, 302-307, 2000.
140. Wargovich MJ, Eng VW, Newmark HL, and Bruce WR: Calcium ameliorates the toxic effect of deoxycholic acid on colonic epithelium. Carcinogenesis 4, 1205-1207, 1983.
141. Chakrabarty S, Radjendirane V, Appelman H, and Varani J: Extracellular calcium and calcium sensing receptor function in human colon carcinomas: Promotion of E-Cadherin expression and suppression of β-catenin/TCF activation. Cancer Res 63, 67-71, 2003.
142. Giovannucci E, Rimm EB, Ascherio A, Stampfer MJ, Colditz GA et al.: Alcohol, low-methionine -low folate diets, and risk of colon cancer in men. JNCI 87, 265-273, 1995.
143. Giovannucci E, Stampfer MJ, Colditz GA, Hunter DJ, Fuchs C, et al.: Multivitamin use, folate and colon cancer in women in the Nurses' Health Study. Ann Intern Med 129, 517-524, 1998.
144. Benito E, Cabeza E, Moreno V, Obrador A, and Bosch FX: Diet and colorectal adenomas: a case-control study in Majorca. Int J Cancer 55, 213-219, 1993.
145. Tseng M, Murray SC, Kupper LL, and Sandler RS: Micronutrients and the risk of colorectal adenomas. Am J Epidemiol 144, 1005-1014, 1996.
146. Su LJ, Arab L: Nutritional status of folate and colon cancer risk: evidence from NHANES I epidemiological follow-up study. Ann Epidemiol 11, 65-72, 2001.
147. Chen J, Giovannucci E, Kelsey K, Rimm EB, Stampfer MJ, et al.: A methylenetetrahydrofolate reductase polymorphism, dietary interactions and risk of colorectal cancer. Cancer Res 57, 1098-1102, 1996.
148. Le Leu RK, Young GP, and McIntosh GH: Folate deficiency reduces the development of colorectal cancer in rats. Carcinogenesis 21, 2261-2265, 2000.
149. Sohn KJ, Puchyr M, Salomon RN, Graeme-Cook F, Fung L, et al.: The effect of dietary folate on APC and p53 mutations in the dimethylhydrazine rat model of colorectal cancer. Carcinogenesis 20, 2345-2350, 1999.
150. Kim YI, Shirwadka S, Choi SW, Puchyr M, Wang Y, et al.: Effects of dietary folate on DNA strand breaks within mutation-proneexons of the p53 gene in rat colon. Gastroenterology 119, 151-161, 2000.
151. Martinez ME, Maltzman T, Marshall JR, Einspahr J, and Reid ME: Risk factors for ki-ras protooncogene mutation in sporadic colorectal adenomas. Cancer Res 59, 5181-5185, 1999.
152. Logan RF, Little J, Hawtin PG, and Hardcastle JD: Effect of aspirin and non-steroidal anti-inflammatory drugs on colorectal adenomas: case-control study of subjects participating in the Nottingham fecal occult blood screening programme. Br Med J 307, 285-289, 1993.
153. Greenberg ER, Baron JA, Freeman DH Jr, Mandel JS, and Haile R: Reduced risk of large-bowel adenomas among aspirin users. The Polyp Prevention Study Group. JNCI 85, 912-916, 1993.
154. Giovannucci E, Rimm E, Stampfer M, Colditz G, Ascherio A, et al.: (1994) Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 121, 241-246, 1994.
155. Slattery ML, Samowitz W, Ballard L, Schaffer D, Leppert M, et al.: A molecular variant of the APC gene at codon 1822: Its association with diet, lifestyle and risk of colon cancer. Cancer Res 61, 1000-1004, 2001.
156. Freedman AN, Michalek AM, Marshall JR, Mettlin CJ, and Petrelli NJ: Familial and nutritional risk factors for p53 over-expression in colorectal cancer. Cancer Epidemiol Biomarkers Prev 5, 285-291, 1996.
157. Gann PH, Manson JE, Glynn RJ, Buring JE, and Hennekens CH: Low-dose aspirin and incidence of colorectal tumors in a randomized trial. JNCI 85, 1220-1224, 1993.
158. Garcia Rodriguez LA and Huerta-Alvarez C: Reduced incidence of colorectal adenoma among long-term users of nonsteroidal inflammatory drugs: a pooled analysis of published studies and a new population-based study. Epidemiology 11, 376-381, 2000.
159. Coogan PF, Rosenberg L, Louik C, Zauber AG, and Stolley PD: NSAIDs and risk of colorectal cancer according to presence or absence of family history of the disease. Cancer Causes Control 11, 249-255, 2000.
160. Phillips RKS, Wallace MH, Lynch PM, Hawk EL, Gordon GB, et al.: A randomized double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 50, 857-861, 2002.
161. Shacter E and Weitzman SA: Chronic inflammation and cancer. Oncology 16, 217-226, 2002.
162. Dannhardt G and Kiefer W: Cyclooxygenase inhibitors: current status and future prospects. Eur J Med Chem 36, 109-126, 2001.
163. Prescott SM, Fitzpatrick FA: Cyclooxgenase-2 and carcinogenesis. Biochim Biophys Acta 1470, 69-78, 2000.
164. Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, et al.: Expression of cyclooxgenase-1 and -2 in human colorectal cancer. Cancer Res 55, 3785-3789, 1999.
165. Kargman SL, O'Neill GP, Vickers PJ, Evans JF, Mancini JA, et al.: Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 55, 2556-2559, 1995.
166. Sun Y, Tang XM, Half E, Kuo Tien M, and Sinicrope FA: Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells. Cancer Res 62, 6323-6328, 2002.
167. Iniguez MA, Rodriguez A, Volpert OV, Fresno M, and Redondo JM: Cyclooxgenase-2: a therapeutic target in angiogenesis. Trends Mol Med 9, 73-78, 2003.
168. Dimberg J, Hugander A, Sirsjo A, and Soderkvist P: Enhanced expression of cyclooxgenase-2 and nuclear beta-catenin are related to mutations in the APC gene in human colorectal cancer. Anticancer Res 21, 911-915, 2001.
169. Dihlmann S, Siermann A, and von Knebel Doeberitz M: The non-steroidal anti-inflammatory drugs aspirin and indomethacin attenuate β-catenin/TCF-4 signaling. Oncogene 20, 645-653, 2001.
170. Shureiqi I and Lippman SM: Lipoxygenase modulation to reverse carcinogenesis. Cancer Res 61, 6307-6312, 2001.
171. Hong SH, Avis I, Vos MD, Martinez A, Treston AM, et al.: Relationship of arcachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors. Cancer Res 59, 2223-2228, 1999.
172. Steele VE, Hawk ET, Viner JL, and Lubert RA: Mechanisms and applications of non-steroidal anti-inflammatory drugs in the chemoprevention of cancer. Mutat Res 523-524, 137-144, 2003.
173. Shureiqi I, Wojno KJ, Poore JA, Reddy RG, Moussalli MJ, et al.: Decrease 13-S-hydroxyocradecadienoic acid level and 15-lipoxygenase-1 expression in human colon cancers. Carcinogenesis 20, 1985-1995, 1999.
174. Shureiqi I, Chen D, Lee JJ, Yang P, Newman RA, et al.: 15-LOX-1: a novel molecular target of nonsteroidal anti-inflammatory drug-induced apoptosis in colorectal cancer cells. JNCI 92, 1136-1142, 2000.
175. Giovannucci E: An updated review of the epidemiological evidence that cigarette smoking increases risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 10, 725-731, 2001.
176. Slattery ML, Curtin K, Anderson K, Ma KN, Ballard L, et al.: Association between cigarette smoking, lifestyle factors, and microsatellite instability in colon cancers. JNCI 92, 1831-1836, 2000.
177. Wu AH, Shibata D, Yu MC, Lai M, and Ross RK: Dietary heterocyclic amines and microsatellite instability in colon adenocarcinomas. Carcinogenesis 22, 1681-1684, 2001.
178. Jacobson JS, Neugut AI, Murray T, Garbowski GC, Forde KA, et al.: Cigarette smoking and other behavioral risk factors for recurrence of colorectal adenomatous polyps. Cancer Causes Control 5, 215-220, 1994.
179. Nanda K, Bastian LA, Hasselblad V, and Simel DL: Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis. Obstet Gynecol 93, 880-888, 1999.
180. Crandall CJ: Estrogen replacement therapy and colon cancer: a clinical review. J Womens Health Gend Based Med 8, 1155-1166, 1999.
181. Franceschi S and La Vecchia C: Colorectal cancer and hormone replacement therapy: an unexpected finding. Eur J Cancer Prev 7, 427-438, 1998.
182. Giacosa A, Franceschi S, La Vecchia C, Favero A, and Andreatta R: Energy intake, overweight, physical exercise and colorectal cancer risk. Eur J Cancer Prev 8, S53-S60, 1999.
183. Steindorf K, Tobiasz-Adamczyk B, Popiela T, Jedrychowski W, Penar A, et al.: Combined risk assessment of physical activity and dietary habits on the development of colorectal cancer. A hospital-based case-control study in Poland. Eur J Cancer Prev 9, 309-316, 2000.
184. Caan BJ, Coates AO, Slattery ML, Potter JD, Quesenberry CP, et al.: Body size and the risk of colon cancer in a large case-control study. Int J Obes Relat Metab Disord 22, 178-184, 1998.
185. Thune I and Furberg AS: Physical activity and cancer risk: dose-response and cancer, all sites and site-specific. Med Sci Sports Exerc 33, S530-50, S609-S610, 2001.
186. Thissen JP, Ketelslegers JM, and Underwood IE: Nutritional regulation of the insulin-like growth factors. Endocrine Reviews 15, 80-101, 1994.
187. Macauley VM: Insulin-like growth factors and cancer. Br J Cancer 65, 311-320, 1992.
188. Ma J, Pollack MN, Giovannucci E, Chan JM, Tao Y et al.: Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF-I) and IGF-binding protein-3. JNCI 91, 620-625, 1999.
189. Kaaks R, Toniolo P, Akhmedkhanov A, Lukanova A, Biessy C, et al.: Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. JNCI 92, 1592-1600, 2000.
190. Elias AN, Pandian M, Wang L, Suarez E, James N, et al.: Leptin and IGF-I levels in unconditioned male volunteers after short-term exercise Psychoneuroendocrinology 25, 453-461, 2000.
191. Roelen CA, DeVries WR, Koppeschaar HP, Vervoorn C, Thijssen JH, et al.: Plasma insulin-like growth factor-I and high affinity growth hormone-binding protein levels increase after two weeks of strenuous physical training. Int J Sports Med 18, 238-241, 1997.
192. Korizis LP, Hickson RC, Chatterton RT Jr, Groseth RT, Christie JM, et al.: Serum levels of total and free IGF-I and IGFBP-3 are increased and maintained in long-term training. Jf App Psychol 86, 1436-1442, 1999.
193. Levi F, Pasche C, Lucchini F, Tavani A, and La Vecchia C: Occupational and leisure time physical activity and the risk of colorectal cancer. Eur J Cancer Prev 8, 487-493, 1999.
194. Vitiello MV, Wilkinson CW, Merriam GR, Moe KE, Prinz P, et al.: Successful 6-month endurance training does not alter IGF-I in healthy older men and women. J Gerontol 52, 149-154, 1997.
195. Consitt LA, Copeland JL, and Tremblay MS: Endogenous anabolic hormone responses to endurance versus resistance exercise and training in women. Sports Med 32, 1-22, 2002.
196. Sun G, Cagnon J, Chagnon YC, Perusse L, Despres JP, et al.: Association and linkage between an insulin-like factor-I gene polymorphism and fat free mass in the HERITAGE family study. Int J Obes Relat Metab Disord 23, 929-935, 1999.
197. Almendingen K, Hofstad B, and Vatn MH: Does high body fatness increase the risk of presence and growth of colorectal adenomas followed up in situ for 3 years? Am J Gastroenterol 96, 2238-2246, 2001.
198. McKeown-Eyssen GE, Holloway C, Jazmaji V, Bright-See E, and Dion P: A randomised trial of vitamin C and E in the prevention of recurrence of colorectal polyps. Cancer Res 48, 4701-4705, 1988.
199. McKeown-Eyssen GE, Bright-See E, Bruce WR, Jazmaji V, and Cohen LB: A randomised trial of a low fat fiber diet in the recurrence of colorectal polyps. Toronto Polyp Prevention Group. J Clin Epidemiol 47, 525-536, 1994.
200. MacLennan R, Macrae F, Bain C, Battistutta D, Chapuis P, et al.: Randomized trial of intake of fat, fiber, and beta carotene to prevent colorectal adenomas. JNCI 87, 1760-1766, 1995.
201. Hofstad B, Almendingen K, Vatn M, Anderson SN, Owen RW, et al.: Growth and recurrence of colorectal polyps: a double-blind 3 year intervention with calcium and antioxidants. Digestion 59, 148-156, 1998.
202. Baron JA, Beach M, Mandel JS, van Stolk RU, Haile RW, et al.: Calcium supplements and colorectal adenomas. Polyp Prevention Study Group. Ann NY Acad Sci 889, 138-145, 1999.
203. Schatzkin A, Lanza E, Corle D, Lance P, Iber F, et al.: Lack of effect of a low-fat, high fiber diet on the recurrence of colorectal adenomas. Polyp Prevention Trial Study Group. N Engl J Med 342, 1149-1155, 2000.
204. Ahlquist AD, Skoletsky JE, Boynton KA, Harrington JJ, Mahoney DW, et al.: Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 119, 1219-1227, 2000.
205. Lauschke H, Caspari R, Friedl W, Schwarz B, Mathiak M, et al.: Detection of APC and k-ras mutations in the serum of patients with colorectal cancer. Cancer Detect Prev 25, 55-61, 2001.